NYMX News and Press, Nymox Pharmaceutical Corporation From 05/23/22

Gainers: Lixiang Education Holding (LXEH) +62%. GeoVax Labs (GOVX) +50%. Sonder Holdings (SOND) +30%. O2Micro International (OIIM) +30%. Evolving Systems (OTC:EVOL) +28%. GoldMining (GLDG) +27%. Neonode (NEON) +24%. Mesa Royalty Trust (MTR) +24%. TRxADE HEALTH (MEDS) +23%. Losers: HIVE Blockc...

Gainers: GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Allarity Therapeutics (ALLR) +14%. Tonix Pharmaceuticals (TNXP) +13%. TRxADE HEALTH (MEDS) +13%. Losers: Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%. NanoViricides...

Shares of NYMOX Pharmaceutical (NASDAQ:NYMX) have plummeted 46% after the company received a Refuse to File letter from the U.S. FDA for its New Drug Application for fexapotide triflutate for benign prostate hyperplasia. The letter said that the company needs longer-term safety data...

IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at 2:48 pm EST, with regard to the Company's New Drug Application (“NDAȁ...

IRVINE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has closed its $6.4 million financing announced in its filing of March 22 with institutional and accredited investors consisting of...

Gainers: BioVie (BIVI) +16%. Progenity (PROG) +16%. Kezar Life Sciences (KZR) +14%. Codiak BioSciences (CDAK) +13%. Ensysce Biosciences (ENSC) +10%. Losers: Nymox Pharmaceutical (NYMX) -29%. HTG Molecular Diagnostics (HTGM) -14%. Zhongchao (ZC...

Nymox Pharmaceutical (NASDAQ:NYMX) entered into definitive agreements with institutional and accredited investors for the purchase and sale of ~3M shares at $1.65/share in a registered direct offering for gross proceeds of ~$5M. NYMX also agreed to issue to the investors, in a concurrent priv...

IRVINE, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of 3,030,304 common shares at a purchase price of $1.65 per shar...

Nymox Pharmaceutical (NYMX +7.8%) submitted a new drug application (NDA) to the FDA for Fexapotide Triflutate to treat men with benign prostatic hyperplasia (BPH). BPH also called prostate gland enlargement can cause uncomfortable urinary symptoms and can also cause bladder, urinary...

IRVINE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company’s New Drug Application (NDA) to the FDA for Fexapotide Triflutate to seek marketing approval...